Phase I study of Wilm's tumor gene WT1 peptide pulsed dendritic cell vaccination combined with gemcitabine for patients with advanced pancreatic cancer.

Trial Profile

Phase I study of Wilm's tumor gene WT1 peptide pulsed dendritic cell vaccination combined with gemcitabine for patients with advanced pancreatic cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2016

At a glance

  • Drugs Tumour peptide-loaded dendritic cell vaccine Tella (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 10 Jan 2013 Planned End Date 1 Mar 2013 added as reported by University Hospital Medical Information Network - Japan.
    • 21 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top